Benign Prostatic Hyperplasia Treatment Market by Treatment Type (Drug Treatment, Surgical Treatment), End User (Home Healthcare Settings, Hospitals & Clinics): Global Market Size Estimates and Forecast (2022-2030)

Code: BMIRE00027014 | Pages: 100 | Industry: Medical Device | Date: Oct 2022 | Type: Global

The market crossed the US$ 11.0 billion mark in 2022 and is expected to hit US$ 18.0 billion by 2030, recording a CAGR of 5.5% during the forecast period.

Rise in Adoption of Minimally Invasive Surgeries

Established types of minimally invasive surgery include electrocautery-based TURP, transurethral incision of the prostate (TUIP), and transurethral vaporization of the prostate (TUVP), although the latter technique is used infrequently. TURP is the most popular minimally invasive surgical procedure for relieving severe medical BPH symptoms, while radical prostatectomy based on open surgery is rarely used in the therapy of BPH, almost solely for indications of prostate cancer.

The adoption of minimally invasive surgeries has been increasing significantly due to various advantages such as less post-operative pain, less blood loss, reduced hospital stays, and faster recovery. This is likely to propel the global benign prostatic hyperplasia (BPH) treatment market during the forecast period.

Within the report, the market is segmented into treatment type, end-user, and geography. On the basis of the treatment type, the market is bifurcated into drug treatment and surgical treatment. Further, by end-user, the market is bifurcated into home healthcare settings, hospitals & clinics. Geographically, the market is segmented into North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa.

Get more information on this report :

COVID-19 impact on benign prostatic hyperplasia treatment market.

The market for benign prostatic hyperplasia treatment is anticipated to be considerably affected due to the outbreak of COVID-19. A large number of hospitals & clinics across the globe were restructured to increase the capacity of hospitals for patients diagnosed with COVID-19. The non-essential procedures took an inherent backlog due to swiftly rising COVID-19 cases. The lockdown led to the disruption of manufacturing and transportation of healthcare essentials. Furthermore, other factors responsible for the impact on the market include restricted availability of medical care, shortage of healthcare staff, and a rise in the burden of COVID-19-related hospitalization. As soon as, the government lifted the restrictions, an undisrupted supply of life-saving drugs and vaccines resumed. Thus, this is expected to lead to a stabilization in the market over time.

The drug treatment segment showcases the high growth of the benign prostatic hyperplasia treatment market.

Based on treatment type, drug treatment can be attributed to accounting highest market share during the analysis period. Medications are commonly preferred as the first line of treatment for benign prostatic hyperplasia (BPH), owing to which the segment is anticipated to hold the largest share during the forecast period.

Recent strategic developments in the benign prostatic hyperplasia treatment market

The benign prostatic hyperplasia treatment market has undergone several significant developments, and a few of these have been mentioned below:

  • In April 2022, Teleflex Incorporated launched UroLift System in Japan for the treatment of benign prostatic hyperplasia (BPH). The FDA had cleared the usage of the UroLift System for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH).
  • In January 2021, PHAREX Health Corporation entered into a partnership with the Philippine Urological Association (PUA), to launch Pharex Tamsulosin for benign prostatic hyperplasia (BPH) treatment.

The benign prostatic hyperplasia treatment market is driven by several players by implementing strategic activities such as Boston Scientific Corporation, GlaxoSmithKline PLC, Olympus Corporation, Abbott, Merck & Co., Inc., Astellas Pharma Inc., Teleflex Incorporated, Unilab, Inc., Lumenis Ltd., and Pharex Health Corporation are among the prominent players operating in the market.

Target audience for the report:

  • Benign prostatic hyperplasia treatment providers
  • Benign Prostatic Hyperplasia -related associations, organizations, forums, and alliances
  • Government bodies, such as regulating authorities
  • Venture capitalists, private equity firms, and start-up companies
  • End users of benign prostatic hyperplasia treatment
  • Research institutes, organizations, and consulting companies

Scope of the report:

In this report, the market has been segmented on the basis of:

  • Treatment Type:
    • Drug Treatment
    • Surgical Treatment
  • End User
    • Home Healthcare Settings
    • Hospitals & Clinics
  • Region
    • North America
    • Europe
    • Asia Pacific (APAC)
    • South & Central America
    • Middle East & Africa
  • Companies profiled
  • Boston Scientific Corporation
  • GlaxoSmithKline PLC
  • Olympus Corporation
  • Abbott
  • Merck & Co., Inc.
  • Astellas Pharma Inc.
  • Teleflex Incorporated
  • Unilab, Inc.
  • Lumenis Ltd.
  • Pharex Health Corporation

The List of Companies
- Boston Scientific Corporation
- GlaxoSmithKline PLC
- Olympus Corporation
- Abbott
- Merck & Co., Inc.
- Astellas Pharma Inc.
- Teleflex Incorporated
- Unilab, Inc.
- Lumenis Ltd.
- Pharex Health Corporation

Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$1500
Site License
$2500
Enterprise License
$3500